TIPARP is a novel independent prognostic biomarker and potential therapeutic target in pancreatic cancer. It contributes to tumor progression by promoting an immunosuppressive microenvironment and activating pro-tumorigenic signaling. These findings highlight TIPARP as a promising candidate for precision medicine and combination immunotherapy in PAAD.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: